Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1365

LM305-hIgG1

Home » Antibodies » LM305-hIgG1

Background of LM305-hIgG1

LM-305 is composed of an anti-GPRC5D monoclonal antibody (mAb), coupled with a protease-degradable linker and a cytotoxic payload known as monomethyl auristatin E (MMAE). This innovative formulation positions LM-305 as a prospective first-in-class ADC (Antibody-Drug Conjugate) targeting GPRC5D. With its unique design and targeting specificity, LM-305 emerges as a promising therapeutic avenue. It signifies a potential breakthrough in offering a novel treatment modality for individuals contending with relapsed/refractory conditions.

Specifications

Catalog Number:
KB-1365
Antibody Name:
LM305-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
GPRC5D
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells DOI: 10.1126/scitranslmed.aau7746.
  2. Joshua Li, et al. The Molecule Pages database. Nature. 2002.